Contraflu PTE LTD is the developer of Cont®aFlu, a breakthrough patent protected product for self treatment of flu and influenza-like illness. This is the first and only product for viral infections that regulates innate host response and thus has no issue of drug resistance. The company has accumulated preclinical and clinical data sufficient to perform the pivotal clinical trial and register Cont®aFlu in the EU.